Nanoscope
Nanoscope co-founder and CEO Sulagna Bhattacharya
Nanoscope Therapeutics Inc., a Bedford biotech company that's developing gene therapies for treatment of retinal degenerative diseases, said Monday it has given the first dose to a human patient in its Phase 2b clinical trial of a drug designed to restore vision in people with retinitis pigmentosa. The company announced in June it won federal Food and Drug Administration approval to move into the trial.